D. Boral Capital Reaffirms Buy Rating for Trevi Therapeutics (NASDAQ:TRVI)

Trevi Therapeutics (NASDAQ:TRVI)‘s stock had its “buy” rating restated by equities research analysts at D. Boral Capital in a research note issued on Wednesday,Benzinga reports. They currently have a $19.00 price objective on the stock. D. Boral Capital’s price objective suggests a potential upside of 77.57% from the company’s previous close.

Several other research analysts also recently weighed in on TRVI. Stifel Nicolaus increased their price target on shares of Trevi Therapeutics from $15.00 to $18.00 and gave the stock a “buy” rating in a research report on Friday, December 19th. Leerink Partners raised their target price on shares of Trevi Therapeutics from $13.00 to $16.00 and gave the stock an “outperform” rating in a research note on Wednesday, November 19th. Oppenheimer reissued an “outperform” rating on shares of Trevi Therapeutics in a research note on Monday, March 9th. HC Wainwright reaffirmed a “buy” rating and issued a $21.00 target price on shares of Trevi Therapeutics in a report on Monday, March 9th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Trevi Therapeutics in a research report on Wednesday, January 21st. Two research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $21.60.

Trevi Therapeutics Price Performance

Shares of TRVI opened at $10.70 on Wednesday. The firm has a market capitalization of $1.37 billion, a P/E ratio of -33.44 and a beta of 0.94. Trevi Therapeutics has a one year low of $4.85 and a one year high of $14.39. The business has a fifty day moving average of $11.14 and a 200 day moving average of $10.93.

Trevi Therapeutics (NASDAQ:TRVI) last posted its earnings results on Tuesday, March 17th. The company reported ($0.06) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.04. Analysts expect that Trevi Therapeutics will post -0.49 EPS for the current fiscal year.

Institutional Investors Weigh In On Trevi Therapeutics

Hedge funds have recently bought and sold shares of the business. Russell Investments Group Ltd. grew its stake in shares of Trevi Therapeutics by 194.5% in the 2nd quarter. Russell Investments Group Ltd. now owns 4,536 shares of the company’s stock worth $25,000 after buying an additional 2,996 shares in the last quarter. Hilton Head Capital Partners LLC bought a new stake in shares of Trevi Therapeutics in the 4th quarter valued at approximately $40,000. Caitong International Asset Management Co. Ltd purchased a new position in shares of Trevi Therapeutics in the 4th quarter worth approximately $50,000. Strs Ohio bought a new stake in Trevi Therapeutics in the first quarter worth $52,000. Finally, Catalyst Funds Management Pty Ltd purchased a new position in Trevi Therapeutics during the second quarter worth $56,000. Hedge funds and other institutional investors own 95.76% of the company’s stock.

Key Stories Impacting Trevi Therapeutics

Here are the key news stories impacting Trevi Therapeutics this week:

• Positive Sentiment: Company says it achieved FDA alignment and plans two pivotal Phase III trials for IPF‑related chronic cough — a major pipeline and regulatory de‑risking milestone that can drive long‑term value if trials and endpoints are favorable. Article Title
• Positive Sentiment: Q4 2025 results topped expectations — EPS of ($0.06) vs. consensus ~($0.0966). The beat and management commentary from the earnings call support near‑term credibility on execution. Earnings Transcript
• Positive Sentiment: Broker support remains strong: Needham raised its target to $24 (Buy) and HC Wainwright reiterated a Buy with a $21 target and updated EPS forecasts — analyst backing increases visibility for upside expectations. Broker Note HC Wainwright Details
• Positive Sentiment: D. Boral Capital reaffirmed a Buy and $19 target, adding to the cluster of buy ratings—positive for investor sentiment and analyst coverage breadth. Article Title
• Neutral Sentiment: Morgan Stanley lowered its price target from $19 to $18 but kept an Overweight rating — still positive sentimentually, but the cut trims some near‑term upside expectations. Article Title
• Negative Sentiment: JonesTrading trimmed its target from $25 to $24 (remains a Buy) — a modest downward adjustment in analyst upside that slightly cools the market’s price‑target momentum. Article Title

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel non-opioid therapies for the management of chronic and acute pain. The company leverages proprietary drug delivery platforms and targeted molecular approaches to address high unmet needs in cancer-related pain, chemotherapy-induced neuropathy and other severe pain conditions.

Its lead product candidate is a proprietary formulation of tetrodotoxin (TTX), a sodium-channel blocking agent being evaluated in early-stage clinical trials for moderate-to-severe pain associated with advanced cancer and peripheral neuropathy.